Boehringer Ingelheim Fremont, Inc.
About Boehringer Ingelheim Fremont, Inc.
Boehringer Ingelheim is a leading research-driven biopharmaceutical company, creating value through innovation in areas of high unmet medical need.
One of the world’s largest manufacturers of biopharmaceuticals, Boehringer Ingelheim is an industry pioneer and has produced more than 40 commercial biopharmaceuticals. Our contract manufacturing business, Boehringer Ingelheim BioXcellence™ reliably supplies innovative therapies that transform lives, today and for generations to come and creates solutions with its partners to improve patient health through its production network spanning the globe, from Biberach, Germany to Vienna, Austria, Shanghai, China and Boehringer Ingelheim Fremont Inc., in California, United States.
A mammalian cell culture center in the San Francisco Bay Area, Boehringer Ingelheim Fremont, Inc., has more than 600 scientists and specialists committed to research, development, and manufacturing to deliver high quality medicines for patients. Our modern facility offers high flexibility with stainless steel and single-use bioreactors for fed-batch and process intensification technology manufacturing. With the complete range of services, from cell line and strain development, including high expression systems, through process development and large-scale manufacturing, to Fill & Finish we help our customers to turn innovative biologic ideas into commercial reality.
Biopharmaceuticals - Competence and Experience for Medicines of the Future Over 35 years ago, Boehringer Ingelheim started developing and producing biopharmaceuticals as one of the first companies worldwide. Biopharmaceuticals are produced by using either mammalian cell cultures or microorganisms such as bacteria or yeast.
1014 articles about Boehringer Ingelheim Fremont, Inc.
-
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets
9/14/2023
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, said on Thursday it is well on track to achieve its 2030 emission reduction targets, and that it had received approval of those targets from the Science Based Targets initiative.
-
Boehringer Ingelheim receives FDA approval for SENVELGO® (velagliflozin oral solution): the first oral liquid medication for diabetes in cats
8/14/2023
Boehringer Ingelheim announced that SENVELGO®, a revolutionary new treatment for cats with diabetes, has been approved by the U.S. Food and Drug Administration.
-
CDR-Life Announces Second Milestone Achievement with Boehringer Ingelheim in Developing Antibody Fragment-based Therapeutics for Geographic Atrophy
8/2/2023
CDR-Life Inc. announced a milestone payment triggered by the achievement of a development milestone with a partnered antibody fragment-based drug candidate that could significantly slow down the progression of geographic atrophy.
-
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
8/1/2023
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continues to advance its pipeline in both Human Pharma and Animal Health expanding across its key therapy areas.
-
Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS (afoxolaner, moxidectin and pyrantel chewable tablets): A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites
7/20/2023
Boehringer Ingelheim announced that the U.S. Food and Drug Administration has approved the newest innovation from the trusted NexGard® Brand of Products — NexGard® PLUS — a monthly beef-flavored soft chew that protects dogs from fleas, ticks, heartworm disease, roundworms and hookworms.
-
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
7/1/2023
Boehringer Ingelheim announced that Cyltezo®, a U.S. Food and Drug Administration -approved Interchangeable biosimilar to Humira®, is now commercially available in the U.S. Cyltezo was initially approved as a biosimilar in 2017 for use in multiple chronic inflammatory diseases.
-
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)
6/23/2023
Boehringer Ingelheim and Zealand Pharma A/S announced additional data demonstrating superior efficacy with survodutide versus placebo in people with overweight or obesity without type 2 diabetes after 46 weeks of treatment.1 The findings were presented at the 2023 American Diabetes Association’s 83rd Scientific Sessions in San Diego, CA, U.S.
-
American Academy of Dermatology launches innovative project to improve outcomes for patients with life-threatening pustular psoriasis
6/22/2023
The American Academy of Dermatology is launching an innovative breakthrough project to develop educational resources to improve the evaluation, diagnosis, and treatment of patients suffering from generalized pustular psoriasis, a rare form of psoriasis that causes widespread, pus-filled blisters, called pustules.
-
Oxford BioTherapeutics and Boehringer Ingelheim Agree on 2 Year Extension to their Second Multi-Year Collaboration in Cancer Immunology
5/25/2023
Oxford BioTherapeutics Ltd., a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate -based therapies, announced that it has extended its second multi-year collaboration with Boehringer Ingelheim for an additional two years.
-
Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight
5/10/2023
Boehringer Ingelheim and Zealand Pharma A/S announced that patients treated with BI 456906 achieved up to 14.9% weight loss after 46 weeks, using the planned maintenance dose.
-
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim - a New Model for Building an External Innovation Ecosystem on an Industry Campus
4/27/2023
BioMed X announced the expansion of its collaboration with Boehringer Ingelheim with the launch of a new model for biomedical research: XSeed Labs.
-
RetinAI Joins Forces with Boehringer Ingelheim to Advance Novel Treatments for Patients with Geographic Atrophy using Artificial Intelligence
4/21/2023
RetinAI Medical AG, a leader in clinical and imaging data management software and advanced analytics using artificial intelligence for ophthalmology, is excited to announce a new partnership with Boehringer Ingelheim.
-
Cognizant and Boehringer Ingelheim Collaborate on Unified Cloud Platform to Speed the Delivery of Life Saving Therapies
4/11/2023
Cognizant announced it is working with Boehringer Ingelheim, a leading research-driven biopharmaceutical company, to advance the speed and quality of medicinal therapy development.
-
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
3/29/2023
Boehringer Ingelheim reported a strong performance in 2022, a year in which 30 million patients benefited from its innovative medicines, while deepening investments in the search for new treatments.
-
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
1/9/2023
Boehringer Ingelheim and 3T Biosciences, announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs.
-
Eli Lilly’s and Boehringer’s Jardiance met its primary outcome in the Phase III EMPA-KIDNEY study, the largest and broadest SGLT2 inhibitor trial in chronic kidney disease.
-
Boehringer Ingelheim Extends the Use of Medidata Rave for Electronic Data Capture in Clinical Trials
10/27/2022
Medidata, a Dassault Systèmes company, and Boehringer Ingelheim announced a five-year renewal of their collaboration in the wider area of electronic data capture.
-
University of Tübingen and Boehringer Ingelheim Join Forces to Lead AI and Data Science R&D for New Medical Breakthroughs
10/20/2022
University of Tübingen, a leading member of Cyber Valley, Europe’s largest Artificial Intelligence research consortium and Boehringer Ingelheim launch an AI and data science fellowship program for top talents from around the world.
-
Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases
10/6/2022
Surrozen, Inc. (Nasdaq: SRZN) announced today that it has entered into a collaboration and license agreement with Boehringer Ingelheim to research and develop SZN-413 for the treatment of retinal diseases.
-
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
9/5/2022
Boehringer Ingelheim announced Phase III data from the InPedILD trial, which assessed the pharmacokinetics and safety profile of nintedanib in children and adolescents between 6 and 17 years old with clinically significant fibrosing interstitial lung disease.